다우존스 지수

브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

등록

홈
인베스팅
주식
영국
LSE
Hyloris Pharmaceuticals Sa (0AB6)
Hyloris Pharmaceuticals Sa (0AB6) 뉴스

0AB6

Hyloris Pharmaceuticals (0AB6)

Hyloris Pharmaceuticals Sa

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:LSE:0AB6

1

일자	시간	출처	헤드라인	심볼	기업
2024/03/14	15:00	UK Regulatory	Hyloris Présente ses Résultats Annuels pour 2023 et ses Perspectives	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/03/14	15:00	UK Regulatory	Hyloris Reports Full Year Results for 2023 & Provides Business Outlook	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/03/14	14:59	UK Regulatory	Communication at the request of the FSMA on the transactions with Qliniq	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/03/14	14:59	UK Regulatory	Communiqué à la requête de la FSMA sur les transactions avec QliniQ	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/03/08	15:00	UK Regulatory	Hyloris to Report 2023 Full-Year Results on 14 March 2024	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/03/08	15:00	UK Regulatory	Hyloris Annonce ses Résultats Financiers Annuels le 14 mars 2024	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/02/28	02:00	UK Regulatory	Hyloris Annonce le Lancement de Maxigesic® IV aux Etats-Unis ainsi que son Approbation au Canada	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/02/28	02:00	UK Regulatory	Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/02/15	02:00	UK Regulatory	Hyloris Recrute un Premier Patient dans le Cadre d'un Essai Clinique de Phase 3 portant sur son Rince-Bouche Breveté Destiné à Contrôler les Saignements lors des Interventions Dentaires	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/02/15	02:00	UK Regulatory	Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/01/30	15:00	UK Regulatory	Hyloris et Purna Female Healthcare Annoncent des Résultats Positifs de leur Essai Clinique de Phase 2 chez des Patientes atteintes de Candidose Vulvovaginale Aiguë (CVV)	LSE:0AB6	Hyloris Pharmaceuticals Sa
2024/01/30	15:00	UK Regulatory	Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)	LSE:0AB6	Hyloris Pharmaceuticals Sa

검색 관련기사 보기:LSE:0AB6

1

Societe Generale null

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관